NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
LYNPARZA (olaparib) by AstraZeneca is poly(adp-ribose) polymerase inhibitors [moa]. Approved for ovarian cancer, breast cancer, prostate cancer and 2 more indications. First approved in 2017.
Drug data last refreshed 22h ago
Mechanism of Action
Poly(ADP-Ribose) Polymerase Inhibitors
Pharmacologic Class:
Poly(ADP-Ribose) Polymerase Inhibitor
Indications (5)
Worked on LYNPARZA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.